ART Advanced Research Technologies Inc.

ART Advanced Research Technologies Inc.

November 29, 2007 15:35 ET

ART Advanced Research Technologies to be Present at the Annual Meeting of the American Society for Cell Biology in Washington, DC

MONTREAL, CANADA--(Marketwire - Nov. 29, 2007) - ART Advanced Research Technologies Inc. ("ART")(TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be exhibiting at the American Society for Cell Biology (ASCB) 47th Annual Meeting, Dec. 1-5, 2007, Washington, DC. ART will showcase its preclinical product offering, including the Optix® MX2 optical imaging device and the Fenestra® line of contrast agents for micro-CT imaging at its booth (#853) located in the Exhibit Hall of the Washington Convention Center. ART's Optix MX2 platform enhances molecular imaging research for the life scientist. By applying ART's proprietary time domain technology to biology a scientist can gain incremental sensitivity, specificity, and depth data from fluorescent labelled compounds. This technique can apply to specific receptors, antibodies, epitopes and drugs for in vivo preclinical research.

As the largest and most important international meeting in the field of cell biology, the ASCB Annual Meeting brings together scientists and students in academia, industry, government, and higher education. Over 100 scientific sessions and 3,500 poster presentations cover a variety of scientific areas within the discipline. With opportunities to learn about the latest research and network with peers, the ASCB Annual Meeting appeals to the diverse interests of the international cell biology community.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (

Contact Information